British journal of cancer
Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study.
Shui-Qing He, Ying Huang, Ze-Yu Zhao, Si-Qing Wen, Shu-Hui Lv, Lin Wang, Wei-Xin Bei, Yan-Qun Xiang, Guo-Ying Liu
Published: 202510.1038/s41416-025-03285-x
Abstract
BACKGROUND: We evaluated the clinical impact of combining capecitabine with immunotherapy (Immu/Cape) compared to immunotherapy monotherapy (Immu) as maintenance in recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) patients following initial…
Preview only. Read the full abstract at the source